ASC

USPTO Trademark Record

ABANDONED

ASCERTAIN - IMPACT OF INTRAVENOUS ABATACEPT ON SYNOVITIS, OSTEITIS AND STRUCTURAL DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE: A RANDOMISED CONTROLLED TRIAL

SN 85525635·Reg 0·Filed Jan 26, 2012

Owner Bristol-Myers Squibb Company

Scientific and technological services and research and design relating thereto; industrial analysis, industrial research and industrial design services; quality control and authentication services; design and development of computer hardware and software.

ASCERTAIN - IMPACT OF INTRAVENOUS ABATACEPT ON SYNOVITIS, OSTEITIS AND STRUCTURAL DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE: A RANDOMISED CONTROLLED TRIAL (Serial No. 85525635), Registration No. 0, is a abandoned US trademark filed on Jan 26, 2012 by Bristol-Myers Squibb Company. This trademark covers Class 042 (Scientific, technology & SaaS services).